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The early pathogenesis of preeclampsia 
(PE) involves a systemic inflammatory 
immune response. Recent data 
demonstrate that increased circulating 
arginine vasopressin (AVP) in humans 
is predictive of PE and that infusion of 
AVP in mouse dams phenocopies the 
pregnancy-specific cardiovascular and 
immune alterations observed in human 
PE. Specifically, AVP suppresses anti-
inflammatory cytokines and cells. 
Betamethasone (BMTZ), commonly 
given to women at risk for preterm birth, 
is both an AVP and immune response 
modulator. We hypothesize that early 
treatment with BMTZ will prevent the 
development of AVP-induced PE.  
C57BL/6J dams were infused with AVP 
(24 ng/hour) or saline throughout 
gestation via osmotic minipump. AVP 
dams received a single subcutaneous 
injection of BMTZ (100ug) early post-
placentation (gestational day (GD) 7). 
Blood pressure was measured 
throughout pregnancy. Total protein was 
measured on 24 hour urine collected on 
GD 17. Maternal and fetal tissues were 
collected on GD 18. Cytokine 
concentrations were determined via 
commercially available ELISAs and 
normalized to total protein.  
BMTZ reversed the hypertension 
(ANOVA n=11, p=0.007) and proteinuria 
(ANOVA n=11, p=0.025) induced by 
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AVP. BMTZ reversed the AVP-induced 
decreases in the maternal and fetal anti-
inflammatory responses. In maternal 
kidney, both anti-inflammatory IL-4 
(AVP: 0.034, n=10 vs BTMZ: 0.092, n=5 
ug/g, p<0.05) and TGFb (AVP: 4.3, 
n=10 vs BTMZ: 9.2, n=5 ug/g, p<0.05) 
were increased in BMTZ-treated dams. 
Decreases in fetal kidney IL-4 (AVP: 
0.013, n=5 vs BTMZ: 0.043, n=5 ug/g, 
p<0.05), IL-10 (AVP: 1.2, n=5 vs BTMZ: 
2.1, n=5 ug/g, p=0.05), and TGFb (AVP: 
1.8, n=5 vs BMTZ: 2.9, n=5 ug/g, 
p<0.05) were reversed with BMTZ 
treatment. Lastly, placental 
concentrations of IL-4 (AVP: 0.002, n=5 
vs BTMZ: 0.005, n=5 ug/g, p<0.05) and 
TGFb (AVP: 0.090, n=5 vs BTMZ: 1.4, 
n=5 ug/g, p<0.05) were also improved 
following BMTZ in AVP-infused dams.  
Supportive of our hypothesis, early 
BMTZ treatment prevented hypertension 
and reduced proteinuria in AVP-infused 
dams. BMTZ also reversed AVP-
induced inhibition of anti-inflammatory 
responses, creating a more tolerogenic 
milieu. These data support the concept 
for the potential use of BMTZ in early 
gestation as a novel preventative agent 
for PE.  
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